Stock detail
Black Diamond (BDTX) stock price, chart, and key data
View Black Diamond stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Black Diamond
BDTX · XNAS
$1.97
+0.51%
+$0.01
Key metrics
52-week range
$2.00 - $0.00
Close price
$1.96
Market cap
$112.6M
P/E ratio
-11.53
Beta
0.71
About the company
Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$10.33
7
Buy
/ 7
Recent calls
08/06/2026
Raymond James
Sean McCutcheon
Buy · Price target $11.00
08/06/2026
Jefferies
Maury Raycroft
Buy · Price target $10.00
08/06/2026
Wedbush
Robert Driscoll
Buy · Price target $14.00
Ticker holders
Review politician disclosures and insider transactions in tabs.
No holder data is available for this category yet.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app